Core Viewpoint - Tevogen Bio Holdings Inc. emphasizes its commitment to capital-efficient operations and sustainable practices in the biotechnology industry, as highlighted in its quarterly report for Q3 2025 [1][8]. Financial Performance - The company reported a loss from operations of $5.7 million for Q3 2025, a 6% decrease compared to Q3 2024 [2][3]. - For the nine months ended September 30, 2025, the operating loss was $21.5 million, reflecting a 51% reduction compared to the same period in 2024 [2][3]. - Total operating expenses for Q3 2025 were $5.7 million, down from $6.1 million in Q3 2024 [3]. - Research and development expenses for Q3 2025 were $3.1 million, compared to $3.3 million in Q3 2024 [3]. - General and administrative expenses decreased to $2.6 million in Q3 2025 from $2.8 million in Q3 2024 [3]. Non-GAAP Financial Metrics - On a non-GAAP basis, the adjusted loss from operations was $2.5 million for Q3 2025, a 10% reduction from $2.8 million in Q3 2024 [5][6]. - For the nine months ended September 30, 2025, the adjusted loss from operations was $7.8 million, a 25% decrease from $10.4 million in the same period of 2024 [5][7]. Strategic Focus - The company aims to transition from traditional high-cost drug development to a more efficient model that emphasizes patient affordability while maintaining profitability [8]. - Tevogen is committed to scalable science and responsible execution, focusing on broad patient access in its pipeline for infectious diseases and oncology [8].